Bead enrichment

Manufactured by Miltenyi Biotec

The Bead Enrichment is a lab equipment product designed for the separation and enrichment of target cells or molecules from complex samples. It utilizes magnetic beads coated with specific antibodies or ligands to capture and isolate the desired targets. The core function of this product is to provide a reliable and efficient method for the purification and concentration of specific cell populations or biomolecules, enabling further downstream analysis and applications.

Automatically generated - may contain errors

Lab products found in correlation

Rag1 mice, by Jackson ImmunoResearch (1 mentions) C57bl 6, by Jackson ImmunoResearch (1 mentions)

Close spelling variants of this product

Magnetic bead enrichment Human CD45 bead enrichment Magnetic bead enrichment method CD11b-positive enrichment beads

2 protocols using bead enrichment

Fate Mapping of Hematopoietic Precursors

Check if the same lab product or an alternative is used in the 5 most similar protocols

To track the progeny of hematopoietic precursors in tumor-bearing
control or Ocn depleted mice, we performed cell fate mapping experiments. We
used bead enrichment (Miltenyi) followed by FACS-based sorting of live lineage
negative congenic CD45.1 cKIT⁺ (CD117) cells (here lineage = B220,
CD19, Ter119, CD11c, CD11b, NK1.1, CD49b, CD127, Ly-6G, CD90.2). The purity of
the sorted CD45.1⁺ cKIT⁺ cells was above 95%. 2.5 ×
10⁵ cells were injected i.v. into tumor-bearing control or Ocn
depleted mice (both CD45.2 genotypes) at 29 days post tumor-injection. 7 days
post-cKit⁺ cell transfer, lung tumor tissue was harvested and
CD45.1⁺ immune cell infiltrates were quantified using flow
cytometry. Non-injected biological controls, Fluorescence Minus One
(FMO)-staining controls and unstained cells were used to analyze the
CD45.1⁺ cell progeny in the tissue.

Engblom C., Pfirschke C., Zilionis R., Martins J.D., Bos S.A., Courties G., Rickelt S., Severe N., Baryawno N., Faget J., Savova V., Zemmour D., Kline J., Siwicki M., Garris C., Pucci F., Liao H.W., Lin Y.J., Newton A., Yaghi O.K., Iwamoto Y., Tricot B., Wojtkiewicz G.R., Nahrendorf M., Cortez-Retamozo V., Meylan E., Hynes R.O., Demay M., Klein A., Bredella M.A., Scadden D.T., Weissleder R, & Pittet M.J. (2017). Osteoblasts remotely supply lung tumors with cancer-promoting SiglecFhigh neutrophils. Science (New York, N.Y.), 358(6367), eaal5081.

+ Open protocol

+ Expand

Adoptive T Cell Therapy for Melanoma

Check if the same lab product or an alternative is used in the 5 most similar protocols

For immunotherapy, C57BL/6, Thy1.1, or Rag1^−/− mice (Jackson Laboratories) were implanted with subcutaneous B16 melanoma (1–5 × 10⁵ cells). At the time of ACT, 10–14 d after implantation, mice (n ≥ 5 for all groups unless otherwise indicated) were injected intravenously with CD8⁺-enriched naive or in vitro activated pmel-1 splenocytes (0.25–10⁶ CD8⁺ Vβ13⁺ T cells), and 0.5–2 × 10⁷ plaque-forming units of recombinant VV-encoding hgp100 and intraperitoneal injections of hIL-2 in PBS (6 × 10⁴ IU/0.5 ml) twice daily for 3 d after adoptive transfer (Palmer et al., 2008 (link)). Mice were randomized, and tumors were blindly measured using digital calipers. The products of the perpendicular diameters are presented as mean ± SEM. At indicated times after ACT, spleens were harvested, ACK-lysed, enumerated, stained, and evaluated by flow cytometry as previously described (Palmer et al., 2008 (link)). Where indicated, congenically marked T cells were isolated using bead enrichment (Miltenyi Biotec or STEMCELL Technologies) from splenocytes, cell number normalized, and co-cultured cognate-peptide–pulsed syngeneic target cells from spleens.

Palmer D.C., Guittard G.C., Franco Z., Crompton J.G., Eil R.L., Patel S.J., Ji Y., Van Panhuys N., Klebanoff C.A., Sukumar M., Clever D., Chichura A., Roychoudhuri R., Varma R., Wang E., Gattinoni L., Marincola F.M., Balagopalan L., Samelson L.E, & Restifo N.P. (2015). Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. The Journal of Experimental Medicine, 212(12), 2095-2113.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!